缺血性卒中静脉溶栓后症状性颅内出血研究进展

doi:10.3969/j.issn.1673-5765.2018.12.016

摘要/Abstract

摘要：

出血转化，尤其症状性颅内出血是缺血性卒中患者急性期静脉溶栓后虽不常见但严重的并发症，其致残率和病死率均较高，严重影响患者预后。我国卒中急性期溶栓率远远落后于欧美国家，临床医生担心出血转化风险是主要原因。本文对溶栓后症状性颅内出血进行综述，以提高临床认识，更好地改进卒中急性期溶栓治疗。

文章导读： 本文对缺血性卒中静脉溶栓后症状性颅内出血的定义、影响因素及处理的研究进展做了总结，重点介绍其临床危险因素、生物学指标和影像学指标。

关键词: 缺血性卒中; 静脉溶栓; 症状性颅内出血; 预测因素; 治疗

Abstract:

Bleeding transformation, especially symptomatic intracranial hemorrhage is an uncommon but serious complication after intravenous thrombolysis in the acute phase of ischemic stroke, which can lead to high disability and mortality. Thrombolysis rate of acute stroke in China was far lower than that in Europe and the United States, the main cause of which was for fear of hemorrhagic transformation risk. This article reviewed the symptomatic hemorrhage after thrombolysis, to provide a reference for safer thrombolytic therapy of acute stroke.

Key words: Ischemic stroke; Intravenous thrombolysis; Symptomatic intracranial hemorrhage;Predictive factor; Treatment

梁志刚, 杨绍婉, 于国平. 缺血性卒中静脉溶栓后症状性颅内出血研究进展[J]. 中国卒中杂志, 2018, 13(12): 1301-1308.

LIANG Zhi-Gang, YANG Shao-Wan, YU Guo-Ping. Progress of Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Ischemic Stroke[J]. Chinese Journal of Stroke, 2018, 13(12): 1301-1308.

参考文献

[1] National Institute of Neurological Disorders

and Stroke rt-PA Stroke Study Group. Tissue

plasminogen activator for acute ischemic stroke[J].

N Engl J Med，1995，333（24）：1581-1587.

[2] The NINDS t-PA Stroke Study Group. Intracerebral

hemorrhage after intravenous t-PA therapy for

ischemic stroke. The NINDS t-PA Stroke Study

Group[J]. Stroke，1997，28（11）：2109-2118.

[3] HACKE W，KASTE M，BLUHMKI E，et al.

Thrombolysis with alteplase 3 to 4. 5 hours after

acute ischemic stroke[J]. N Engl J Med，2008，359

（13）：1317-1329.

[4] MIKULIK R，WAHLGREN N. Treatment of acute

stroke：an update[J]. J Intern Med，2015，278（2）：

145-165.

[5] HAMANN G F，DEL ZOPPO G J，VON KUMMER

R. Hemorrhagic transformation of cerebral

infarction--possible mechanisms[J]. Thromb

Haemost，1999，82（Suppl 1）：92-94.

[6] YAGHI S，EISENBERGER A，WILLEY J Z.

Symptomatic intracerebral hemorrhage in acute

ischemic stroke after thrombolysis with intravenous

recombinant tissue plasminogen activator：a review

of natural history and treatment[J]. JAMA Neurol，

2014，71（9）：1181-1185.

[7] HORSTMANN S，KALB P，KOZIOL J，et al.

Profiles of matrix metalloproteinases，their inhibitors，

and laminin in stroke patients：influence of different

therapies[J]. Stroke，2003，34（9）：2165-2170.

[8] LARRUE V，VON KUMMER R R，MÜLLER

A，et al. Risk factors for severe hemorrhagic

transformation in ischemic stroke patients treated

with recombinant tissue plasminogen activator：a

secondary analysis of the European-Australasian

Acute Stroke Study（ECASS Ⅱ）[J]. Stroke，2001，32

（2）：438-441.

[9] WAHLGREN N，AHMED N，DÁVALOS A，et

al. Thrombolysis with alteplase for acute ischaemic

stroke in the Safe Implementation of Thrombolysis

in Stroke-Monitoring Study（SITS-MOST）：an

observational study[J]. Lancet，2007，369（9558）：

275-282.

[10] HACKE W，KASTE M，FIESCHI C，et al.

Randomised double-blind placebo-controlled

trial of thrombolytic therapy with intravenous

alteplase in acute ischaemic stroke（ECASS Ⅱ）.

Second European-Australasian Acute Stroke Study

Investigators[J]. Lancet，1998，352（9136）：1245-

1251.

[11] SYLAJA P N，COTE R，BUCHAN A M，et al.

Thrombolysis in patients older than 80 years with

acute ischaemic stroke：Canadian Alteplase for

Stroke Effectiveness Study[J]. J Neurol Neurosurg

Psychiatry，2006，77（7）：826-829.

[12] BHATNAGAR P，SINHA D，PARKER R A，et al.

Intravenous thrombolysis in acute ischaemic stroke：

a systematic review and meta-analysis to aid decision

making in patients over 80 years of age[J]. J Neurol

Neurosurg Psychiatry，2011，82（7）：712-717.

[13] IST-3 collaborative group，SANDERCOCK P，

WARDLAW J M，et al. The benefits and harms of

intravenous thrombolysis with recombinant tissue

plasminogen activator within 6 h of acute ischaemic

stroke（the third international stroke trial [IST-3]）：

a randomised controlled trial[J]. Lancet，2012，379

（9834）：2352-2363.

[14] HEMMEN T M，RAPP K S，EMOND J A，et al.

Analysis of the National Institute of Neurological

Disorders and Stroke tissue plasminogen activator

studies following European Cooperative Acute

Stroke Study III patient selection criteria[J]. J Stroke

Cerebrovasc Dis，2010，19（4）：290-293.

[15] 重组组织型纤溶酶原激活剂治疗缺血性卒中共识

专家组. 临床应用重组组织型纤溶酶原激活剂静脉

溶栓治疗缺血性卒中专家共识[J]. 中华内科杂志，

2006，45（7）：613-614.

[16] CAPPELLARI M，BOVI P，MICHELETTI N，et al.

The risk stratification based on the CHA2DS2-VASc

may predict the response to intravenous thrombolysis

after stroke[J]. J Neurol，2013，260（10）：2681-2683.

[17] KABLAU M，KREISEL S H，SAUER T，et

al. Predictors and early outcome of hemorrhagic

transformation after acute ischemic stroke[J].

Cerebrovasc Dis，2011，32（4）：334-341.

[18] 郭义坤，李焰生. 急性脑梗死患者重组组织型纤溶酶

原激活物静脉溶栓后脑出血[J]. 国际脑血管病杂志，

2010，18（2）：113-118.

[19] 中华医学会神经病学分会，中华医学会神经病学分

会脑血管病学组. 中国急性缺血性脑卒中诊治指南

2014[J]. 中华神经科杂志，2015，48（4）：246-257.

[20] MOKIN M，KASS-HOUT T，KASS-HOUT O，et

al. Blood pressure management and evolution of

thrombolysis-associated intracerebral hemorrhage in

acute ischemic stroke[J]. J Stroke Cerebrovasc Dis，

2012，21（8）：852-859.

[21] DEREX L，NIGHOGHOSSIAN N. Intracerebral

haemorrhage after thrombolysis for acute ischaemic

stroke：an update[J]. J Neurol Neurosurg Psychiatry，

2008，79（10）：1093-1099.

[22] KASE C S，FURLAN A J，WECHSLER L R，

et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke：the PROACT Ⅱ

trial[J]. Neurology，2001，57（9）：1603-1610.

[23] MISHRA N K，DAVIS S M，KASTE M，et al.

Comparison of outcomes following thrombolytic

therapy among patients with prior stroke and

diabetes in the Virtual International Stroke Trials

Archive（VISTA）[J]. Diabetes Care，2010，33（12）：

2531-2537.

[24] BANG O Y，SAVER J L，KIM S J，et al. Collateral

flow averts hemorrhagic transformation after

endovascular therapy for acute ischemic stroke[J].

Stroke，2011，42（8）：2235-2239.

[25] JAUCH E C，SAVER J L，ADAMS H P JR，et al.

Guidelines for the early management of patients with

acute ischemic stroke：a guideline for healthcare

professionals from the American Heart Association/

American Stroke Association[J]. Stroke，2013，44

（3）：870-947.

[26] SAPOSNIK G，GLADSTONE D，RAPTIS R，et

al. Atrial fibrillation in ischemic stroke：predicting

response to thrombolysis and clinical outcomes[J].

Stroke，2012，44（1）：99-104.

[27] VERGOUWEN M D，CASAUBON L K，SWARTZ

R H，et al. Subtherapeutic warfarin is not associated

with increased hemorrhage rates in ischemic strokes

treated with tissue plasminogen activator[J]. Stroke，

2011，42（4）：1041-1045.

[28] XIAN Y，LIANG L，SMITH E E，et al. Risks of

intracranial hemorrhage among patients with acute

ischemic stroke receiving warfarin and treated with

intravenous tissue plasminogen activator[J]. JAMA，

2012，307（24）：2600-2608.

[29] MAZYA M，EGIDO J A，FORD G A，et al.

Predicting the risk of symptomatic intracerebral

hemorrhage in ischemic stroke treated with

intravenous alteplase：safe Implementation

of Treatments in Stroke（SITS）symptomatic

intracerebral hemorrhage risk score[J]. Stroke，2012，

43（6）：1524-1531.

[30] DORADO L，MILLÁN M，DE LA OSSA N P，et al.

Influence of antiplatelet pre-treatment on the risk of

intracranial haemorrhage in acute ischaemic stroke

after intravenous thrombolysis[J]. Eur J Neurol，

2010，17（2）：301-306.

[31] GROTTA J C，WELCH K M，FAGAN S C，et al.

Clinical deterioration following improvement in the

NINDS rt-PA Stroke Trial[J]. Stroke，2001，32（3）：

661-668.

[32] GUO Y，YAN S，ZHANG S，et al. Lower serum

calcium level is associated with hemorrhagic

transformation after thrombolysis[J]. Stroke，2015，

46（5）：1359-1361.

[33] INOUE Y，MIYASHITA F，TOYODA K，et al. Low

serum calcium levels contribute to larger hematoma

volume in acute intracerebral hemorrhage[J]. Stroke，

2013，44（7）：2004-2006.

[34] HARRIS A K，ERGUL A，KOZAK A，et al. Effect

of neutrophil depletion on gelatinase expression，

edema formation and hemorrhagic transformation

after focal ischemic stroke[J/OL]. BMC Neurosci，

2005，6：49. https：//doi.org/10.1186/1471-2202-6-49.

[35] ROSELL A，CUADRADO E，ORTEGA-AZNAR

A，et al. MMP-9-positive neutrophil infiltration is

associated to blood-brain barrier breakdown and

basal lamina type IV collagen degradation during

hemorrhagic transformation after human ischemic

stroke[J]. Stroke，2008，39（4）：1121-1126.

[36] CASTELLANOS M，LEIRA R，SERENA J，et al.

Plasma cellular-fibronectin concentration predicts

hemorrhagic transformation after thrombolytic

therapy in acute ischemic stroke[J]. Stroke，2004，35

（7）：1671-1676.

[37] JICKLING G C，LIU D，STAMOVA B，et al.

Hemorrhagic transformation after ischemic stroke in

animals and humans[J]. J Cereb Blood Flow Metab，

2014，34（2）：185-199.

[38] CRAIGE S M，CHEN K，PEI Y，et al. NADPH

oxidase 4 promotes endothelial angiogenesis through

endothelial nitric oxide synthase activation[J].

Circulation，2011，124（6）：731-740.

[39] LIN K，KAZMI K S，LAW M，et al. Measuring

elevated microvascular permeability and predicting

hemorrhagic transformation in acute ischemic stroke

using first-pass dynamic perfusion CT imaging[J].

AJNR Am J Neuroradiol，2007，28（7）：1292-1298.

[40] OZKUL-WERMESTER O，GUEGANMASSARDIER

E，TRIQUENOT A，et al. Increased

blood-brain barrier permeability on perfusion

computed tomography predicts hemorrhagic

transformation in acute ischemic stroke[J]. Eur

Neurol，2014，72（1-2）：45-53.

[41] JAIN A R，JAIN M，KANTHALA A R，et al.

Association of CT perfusion parameters with

hemorrhagic transformation in acute ischemic

stroke[J]. AJNR Am J Neuroradiol，2013，34（10）：

1895-1900.

[42] BANG O Y，SAVER J L，KIM S J，et al. Collateral

flow predicts response to endovascular therapy for

acute ischemic stroke[J]. Stroke，2011，42（3）：693-

699.

[43] SILLANPÄÄ N，SAARINEN J T，RUSANEN

H. Computed tomography angiography source images closely reflect the integrity of collateral

circulation[J]. J Neuroradiol，2015，42（5）：261-268.

[44] RUSANEN H，SAARINEN J T，SILLANPÄÄ N.

Collateral Circulation Predicts the Size of the Infarct

Core and the Proportion of Salvageable Penumbra

in Hyperacute Ischemic Stroke Patients Treated with

Intravenous Thrombolysis[J]. Cerebrovasc Dis，2015，

40（3-4）：182-190.

[45] CHARIDIMOU A，PASI M，FIORELLI M，et al.

Leukoaraiosis，Cerebral Hemorrhage，and Outcome

After Intravenous Thrombolysis for Acute Ischemic

Stroke：A Meta-Analysis（v1）[J]. Stroke，2016，47

（9）：2364-2372.

[46] LIN Q，LI Z，WEI R，et al. Increased Risk of Post-

Thrombolysis Intracranial Hemorrhage in Acute

Ischemic Stroke Patients with Leukoaraiosis：A

Meta-Analysis[J/OL]. PLoS One，2016，11（4）：

e0153486. https：//doi.org/10.1371/journal.

pone.0153486.

[47] DEMCHUK A M，KHAN F，HILL M D，et

al. Importance of leukoaraiosis on CT for tissue

plasminogen activator decision making：evaluation

of the NINDS rt-PA Stroke Study[J]. Cerebrovasc

Dis，2008，26（2）：120-125.

[48] CONFORTO A B，LUCATO L T，LEITE CDA

C，et al. Cerebral microbleeds and intravenous

thrombolysis：case report[J]. Arq Neuropsiquiatr，

2006，64（3B）：855-857.

[49] FIEHLER J，ALBERS G W，BOULANGER J M，et

al. Bleeding risk analysis in stroke imaging before

thromboLysis（BRASIL）：pooled analysis of T2

*-

weighted magnetic resonance imaging data from 570

patients[J]. Stroke，2007，38（10）：2738-2744.

[50] PANTONI L. Cerebral small vessel disease：from

pathogenesis and clinical characteristics to

therapeutic challenges[J]. Lancet Neurol，2010，9

（7）：689-701.

[51] LOU M，SAFDAR A，MEHDIRATTA M，et al. The

HAT Score：a simple grading scale for predicting

hemorrhage after thrombolysis[J]. Neurology，2008，

71（18）：1417-1423.

[52] SAPOSNIK G，FANG J，KAPRAL M K，et al. The

iScore predicts effectiveness of thrombolytic therapy

for acute ischemic stroke[J]. Stroke，2012，43（5）：

1315-1322.

[53] MAZYA M，EGIDO J A，FORD G A，et al.

Predicting the risk of symptomatic intracerebral

hemorrhage in ischemic stroke treated with

intravenous alteplase：safe Implementation

of Treatments in Stroke（SITS）symptomatic

intracerebral hemorrhage risk score[J]. Stroke，2012，

43（6）：1524-1531.

[54] STRBIAN D，ENGELTER S，MICHEL P，et al.

Symptomatic intracranial hemorrhage after stroke

thrombolysis：the SEDAN score[J]. Ann Neurol，

2012，71（5）：634-641.

[55] MENON B K，SAVER J L，PRABHAKARAN S，et

al. Risk score for intracranial hemorrhage in patients

with acute ischemic stroke treated with intravenous

tissue-type plasminogen activator[J]. Stroke，2012，

43（9）：2293-2299.

[56] SAPOSNIK G，GUZIK A K，REEVES M，et al.

Stroke Prognostication using Age and NIH Stroke

Scale：SPAN-100[J]. Neurology，2013，80（1）：21-

28.

[57] FLINT A C，FAIGELES B S，CULLEN S P，et al.

THRIVE score predicts ischemic stroke outcomes

and thrombolytic hemorrhage risk in VISTA[J].

Stroke，2013，44（12）：3365-3369.

[58] HILL M D，BUCHAN A M; Canadian Alteplase for

Stroke Effectiveness Study（CASES）Investigators.

Thrombolysis for acute ischemic stroke：results of

the Canadian Alteplase for Stroke Effectiveness

Study[J]. CMAJ，2005，172（10）：1307-1312.

[59] YAGHI S，BOEHME A K，DIBU J，et al. Treatment

and Outcome of Thrombolysis-Related Hemorrhage：

A Multicenter Retrospective Study[J]. JAMA Neurol，

2015，72（12）：1451-1457.

[60] YAGHI S，WILLEY J Z，CUCCHIARA B，et

al. Treatment and outcome of hemorrhagic

transformation after intravenous Alteplase in acute

ischemic stroke：a scientific statement for healthcare

professionals from the American Heart Association/

American Stroke Association[J/OL]. Stroke，2017，

48（12）：e343-e361. http：//doi.org/10.1161/

STR.0000000000000152.